A Study in Myeloproliferative Disorders

Status:
Completed

Trial end date:
2018-02-22

Target enrollment:

Participant gender:

The purpose of this study is to find out the safe dose range of the study drug in patients with myeloproliferative disorders.

Phase 1

Eli Lilly and Company